



**ACC.21**

# Health Status Benefits of Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results from the Explorer-HCM Randomized Clinical Trial

**John Spertus, MD MPH**

Lauer/Missouri Endowed Chair and Professor,  
UMKC and Saint Luke's Mid America Heart  
Institute

@jspertus

On behalf of the EXPLORER-HCM investigators



AMERICAN  
COLLEGE of  
CARDIOLOGY

# Disclosures

- Presenting author
  - Consultant for Abbott, Amgen, Bayer, Janssen Pharmaceuticals, Merck & Co., MyoKardia Inc., Novartis, UnitedHealthcare
  - Grant Support from Abbott Vascular
  - Copyright to the SAQ, KCCQ and PAQ
  - Member, Board of Directors Blue Cross Blue Shield of Kansas City


This study was funded by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb

The logo for ACC.21 is displayed on a white, tilted rectangular background. The text "ACC.21" is written in a bold, sans-serif font, with "ACC." in dark blue and ".21" in light blue. The background of the slide features a blue gradient at the bottom with abstract red and white circular patterns.


**ACC.21**

# Background

- Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder
  - Unexplained left ventricular (LV) hypertrophy
  - Often caused by pathogenic variants in sarcomeric genes
- A primary treatment goal is to improve symptoms and function
  - Current therapies include beta-blockers, verapamil, disopyramide
  - Invasive options are considered for refractory symptoms
- Mavacamten, a direct myosin inhibitor, decreases contractility & improves peak  $\text{VO}_2$ ,<sup>1</sup> but its impact on patients' health status – their symptoms, function and quality of life – is incompletely understood



# Mavacamten: Mechanism of Action




**Mavacamten is a targeted inhibitor of cardiac myosin that reduces the number of myosin-actin cross-bridges and decreases contractility**

**ACC.21**


# EXPLORER-HCM Study Design

## Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial in Patients with Obstructive HCM<sup>1</sup>

Patients with LVOT gradient  $\geq 50$  mmHg and New York Heart Association (NYHA) class II-III symptoms were randomized 1:1 to receive once-daily oral mavacamten (starting dose of 5 mg with a 2-step dose titration) or placebo for 30 weeks



### Quality of Life Assessed with the Kansas City Cardiomyopathy Questionnaire



ACC.21

# Quantifying Patients' Health Status

- Kansas City Cardiomyopathy Questionnaire
    - 23-item disease-specific questionnaire quantifying
      - Symptoms
      - Physical Function
      - Social Function
      - Quality of Life
- Clinical Summary Score**
- Overall Summary Score**
- Range = 0-100, with higher scores indicating fewer symptoms, better function/QoL
  - 5-, 10- and 20-point changes = small, mod-large and large-very large changes<sup>1-3</sup>
  - Cognitive interviews confirmed relevance and understandability of the KCCQ to patients with oHCM
  - Extensive analyses of missing data suggested no biases

# Methods

- Changes from baseline KCCQ scores plotted (means $\pm$ SE) over time
- Comparisons performed using mixed model repeated measures analyses with primary outcome the differences at 30 weeks
  - Fixed effects: treatment, baseline KCCQ and variables used in stratification
    - NYHA Class, beta blocker use, planned ergometer type
  - Interaction between Treatment and Time
- Responder analyses to inform the observed mean differences
  - Worsened ( $\leq$ -5 points)
  - Unchanged (-5 to <5 points)
  - Small Improvement (5 to <10 points)
  - Moderate to Large Improvement (10 to <20 points)
  - Large to Very Large Improvement ( $\geq$ 20 points)

# Demographics and Baseline Characteristics

	Mavacamten (N=98)	Placebo (N=96)
Age, years	57.8 ± 12.7	58.2 ± 11.6
Male, n (%)	56 (57.1)	62 (64.6)
Beta-blocker users, n (%)	79 (80.6)	69 (71.9)
Calcium channel blocker users, n (%)	16 (16.3)	15 (15.6)
pVO <sub>2</sub> , mL/kg/min	19.3 ± 5.1	19.9 ± 5.1
NYHA class, n (%)		
Class II	70 (71.4)	71 (74.0)
Class III	28 (28.6)	25 (26.0)
KCCQ Overall Summary score	67.2 ± 17.2	65.7 ± 19.6
KCCQ Clinical Summary score	70.9 ± 16.3	70.3 ± 19.0


Data are mean ± standard deviation.



**ACC.21**



# Mean change in KCCQ-Overall Summary Score



Difference in KCCQ-OS = +9.1 (95% CI: 5.5,12.8)


## ON TREATMENT

### Number of Subjects with Non-Missing Data per Week

	0	6	12	18	30
—■— Mavacamten	98	89	90	90	92
—■— Placebo	96	82	91	93	88

# Amongst Largest Mean KCCQ-OS Differences of any Medication


TRIALS REPORTING MEAN DIFFERENCE OF CHANGE IN KCCQ-OS SCORES



# Responder Analyses to Support Interpretation<sup>1</sup>



= Marked Improvement




= Minimal Change





= Marked Deterioration

Outcomes from a Study

Mean Treatment Difference




Distribution of Change



# Percentage of Participants Who Changed by Clinically Important Amounts at 30 Weeks

- A greater proportion of patients taking mavacamten achieved a very large clinically meaningful improvement in the KCCQ ( $\geq 20$ -point) compared to placebo
- A greater proportion of patients in the placebo arm had no change or deterioration in their health status at Week 30

23% vs. 9%  
NNT = ~7



36% vs. 15%  
NNT = ~5

Categories of Clinical Change in KCCQ Overall Summary Score

ACC.21

# Limitations

- 28% of patients missing either baseline or follow-up KCCQ data
  - Extensive analyses suggest no observable biases
- EXPLORER-HCM included patients with hemodynamically significant oHCM
  - Whether comparable benefits would be observed in other patient HCM populations requires additional study
- Longer term studies are needed to understand longer-term outcomes

# Conclusions

- Mavacamten is associated with substantial health status improvements in patients with symptomatic oHCM
  - NNT for a large-to-very large improvement = ~5
- Benefits are observed early after treatment
- Benefits regress with treatment withdrawal
- Illuminating the benefits to patients can inform discussions on the use of mavacamten for oHCM

# **I would like to thank:**

## **Fellow co-authors:**

Jennifer T Fine, PhD, Perry Elliott, MD, Carolyn Y Ho, MD, Iacopo Olivotto, MD, Sara Saberi, MD, Wanying Li, PhD, Chantal Dolan, PhD, Matthew Reaney, MS, Amy J Sehnert, MD, Daniel Jacoby, MD

## **All EXPLORER-HCM investigators**

**Study coordinators, core laboratories, and MyoKardia**

**Especially, the patients and their families**

The logo for ACC.21 is a white, rounded rectangular shape with a slight shadow, containing the text "ACC.21" in a bold, blue, sans-serif font. The background of the slide features a blue gradient at the bottom with abstract red and white circular patterns.

**ACC.21**

# Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial



*John A Spertus, Jennifer T Fine, Perry Elliott, Carolyn Y Ho, Iacopo Olivotto, Sara Saberi, Wanying Li, Chantal Dolan, Matthew Reaney, Amy J Sehnert, Daniel Jacoby*

## Summary

**Background** Improving symptoms is a primary treatment goal in patients with obstructive hypertrophic cardiomyopathy. Currently available pharmacological options for hypertrophic cardiomyopathy are not disease-specific and are often inadequate or poorly tolerated. We aimed to assess the effect of mavacamten, a first-in-class cardiac myosin inhibitor, on patients' health status—ie, symptoms, physical and social function, and quality of life.

**Methods** We did a health status analysis of EXPLORER-HCM, a phase 3, double-blind, randomised, placebo-controlled trial. The study took place at 68 clinical cardiovascular centres in 13 countries. Adult patients ( $\geq 18$  years) with symptomatic obstructive hypertrophic cardiomyopathy (gradient  $\geq 50$  mm Hg and New York Heart Association class II–III) were randomly assigned (1:1) to mavacamten or placebo for 30 weeks, followed by an 8-week washout period. Both patients and staff were masked to study treatment. The primary outcome for this secondary analysis was the Kansas City Cardiomyopathy Questionnaire (KCCQ), a well validated disease-specific measure of patients' health status. It was administered at baseline and weeks 6, 12, 18, 30 (end of treatment), and 38 (end of study). Changes from baseline to week 30 in KCCQ overall summary (OS) score and all subscales were analysed using mixed model repeated measures. This study is registered with ClinicalTrials.gov, NCT03470545.

Published Online

May 15, 2021

[https://doi.org/10.1016/S0140-6736\(21\)00763-7](https://doi.org/10.1016/S0140-6736(21)00763-7)

See Online/Comment

<https://doi.org/10.1016/PII>

Saint Luke's Mid America Heart Institute, Kansas City, MO, USA (Prof J A Spertus MD); University of Missouri, Kansas City, MO, USA (Prof J A Spertus); MyoKardia, a Bristol Myers Squibb company, Brisbane, CA, USA (J T Fine PhD, W Li PhD, A J Sehnert MD); Centre for Heart Muscle

ACC.21




# Backup Slides/Alternatives

**ACC.21**


The footer features a blue background with a stylized red fire hydrant and a white sign with the text 'ACC.21' in blue. The sign is tilted and has a slight shadow.

# Change from baseline overtime in KCCQ scales


**A** KCCQ Total Symptom Scale




**B** KCCQ Physical Limitation Scale




**E** KCCQ Clinical Summary Scale



**C** KCCQ Social Limitation Scale



**D** KCCQ Quality of Life Scale



**ACC.21**

# Responder Analyses for KCCQ scales from baseline to Week 30

